MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202617072407 A) filed by Ascidian Therapeutics, Inc. on June 11, 2026, for Mecp2 Trans-Splicing Molecules.
Inventors include Clemens, Adam; Gray, Jesse; and Burkhart, Kirk.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: Exon editor constructs are provided, which include a binding domain that binds a target intron of a MeCP2 pre-mRNA, a hemi-intron, and a coding domain comprising one or more MeCP2 exons. Also provided are methods of expressing functional MeCP2 in a target cell that include contacting a target cell with exon editor constructs provided herein.
Disclaimer: Curated by HT Syndication.
